Growth Metrics

United Therapeutics (UTHR) Depreciation & Amortization (CF) (2016 - 2026)

United Therapeutics' Depreciation & Amortization (CF) history spans 17 years, with the latest figure at $22.8 million for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 15.74% to $22.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $85.6 million, a 18.07% increase, with the full-year FY2025 number at $85.6 million, up 18.07% from a year prior.
  • Depreciation & Amortization (CF) hit $22.8 million in Q4 2025 for United Therapeutics, up from $21.9 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for UTHR hit a ceiling of $22.8 million in Q4 2025 and a floor of $12.4 million in Q2 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $15.6 million across 5 years, with a median of $13.3 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): decreased 3.82% in 2021 and later soared 44.96% in 2024.
  • Tracing UTHR's Depreciation & Amortization (CF) over 5 years: stood at $12.6 million in 2021, then increased by 4.76% to $13.2 million in 2022, then increased by 3.79% to $13.7 million in 2023, then soared by 43.8% to $19.7 million in 2024, then grew by 15.74% to $22.8 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for UTHR at $22.8 million in Q4 2025, $21.9 million in Q3 2025, and $21.1 million in Q2 2025.